These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 7228202)

  • 1. In vivo and in vitro availability of commercial phenytoin formulations containing phenobarbitone.
    Shukla UA; Gokhale RD; Tipnis HP; Kulkarni RD; Worlikar PS
    Indian J Med Res; 1980 Dec; 72():910-5. PubMed ID: 7228202
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of formulation on dissolution and bioavailability of phenytoin tablets.
    Chakrabarti S; Belpaire F; Moerman E
    Pharmazie; 1980; 35(10):627-9. PubMed ID: 7454745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein binding of antiepileptic drugs in Sri Lankans.
    Karunanayake EH; Joice PD; Peiris JB; Meijer JW; Meinardi H
    Ceylon Med J; 1990 Mar; 35(1):25-8. PubMed ID: 2361227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dissolution rates and bioavailability of phenytoin preparations (author's transl)].
    Brandau R; Wehnert HU
    Arzneimittelforschung; 1979; 29(3):552-5. PubMed ID: 582744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relative bioavailability of phenytoin and barbiturates in single or combined preparations].
    Procaccianti G; Albani F; Riva R; Baruzzi A
    Boll Chim Farm; 1981 Dec; 120(12):725-9. PubMed ID: 7344726
    [No Abstract]   [Full Text] [Related]  

  • 6. Experimental study on combined treatment with phenobarbitone and dipenylhydantoin.
    Frey HH; Kampmann E; Nielsen CK
    Acta Pharmacol Toxicol (Copenh); 1967; 25():Suppl 4:66. PubMed ID: 5630959
    [No Abstract]   [Full Text] [Related]  

  • 7. Interactions between phenytoin, phenobarbitone and other drugs.
    Drug Ther Bull; 1976 Feb; 14(4):13-6. PubMed ID: 1248371
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of phenobarbital on diphenylhydantoin metabolism in children.
    Buchanan RA; Heffelfinger JC; Weiss CF
    Pediatrics; 1969 Jan; 43(1):114-6. PubMed ID: 5764058
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticonvulsant activity of phenobarbital and phenytoin in combination.
    Leppik IE; Sherwin AL
    J Pharmacol Exp Ther; 1977 Mar; 200(3):570-5. PubMed ID: 850129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers.
    Amabeoku GJ; Chikuni O; Akino C; Mutetwa S
    East Afr Med J; 1993 Feb; 70(2):90-3. PubMed ID: 8513749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenylsuccinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model.
    Luszczki JJ; Cioczek JD; Kocharov SL; Andres-Mach M; Kominek M; Zolkowska D
    Eur J Pharmacol; 2010 Dec; 648(1-3):74-9. PubMed ID: 20826140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo availability of hydrophilized phenytoin from capsules.
    Lerk CF; Lagas M; Lie-a-Huen L; Broersma P; Zuurman K
    J Pharm Sci; 1979 May; 68(5):634-8. PubMed ID: 430506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Consequeces of the elimination of a combination drug. Transition from combination antisacer: attention].
    de Crousaz G; Schelling JL
    Schweiz Med Wochenschr; 1977 Dec; 107(51):1932-6. PubMed ID: 594737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of phenytoin. Comparison of data obtained in vitro, in healthy volunteers and in epileptic patients].
    Albani F; Pazzaglia P; Procaccianti G; Riva R; Baruzzi A
    Boll Chim Farm; 1981 Dec; 120(12):715-24. PubMed ID: 7344725
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro and in vivo characteristics of some commercial phenobarbital tablets.
    Sylvestri MF; Ueda CT
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):492-7. PubMed ID: 528095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diphenylhydantoin substrate induced difference spectra: inhibition by other anticonvulsant drugs.
    Patsalos PN; Lascelles PT
    Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):31-43. PubMed ID: 6102406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute polyneuropathy caused by diphenylhydantoin intoxication (author's transl)].
    Meienberg O; Bajc O
    Dtsch Med Wochenschr; 1975 Jul; 100(29):1532-4, 1539. PubMed ID: 168051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of phenobarbital and SKF 525A pretreatment on diphenylhydantoin teratogenicity in mice.
    Harbison RD; Becker BA
    J Pharmacol Exp Ther; 1970 Nov; 175(2):283-8. PubMed ID: 5481698
    [No Abstract]   [Full Text] [Related]  

  • 19. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro.
    Sorrell TC; Forbes IJ
    Clin Exp Immunol; 1975 May; 20(2):273-85. PubMed ID: 1212810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of orthogonal functions to the spectrophotometric determination of phenytoin and phenobarbitone in pharmaceutical preparations.
    Amer MM; Ahmad AK; Hassan SM
    J Pharm Pharmacol; 1977 Jun; 29(6):355-7. PubMed ID: 18572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.